PlainRecalls
FDA Drug Moderate Class II Completed

Oxybutynin Chloride Extended-Release Tablet USP, 5 mg, 100 count bottles, Rx Only, Manufactured by: Cadila Healthcare Ltd, Baddi, India. Distributed by: Zydus Pharmaceuticals (USA) Inc. NDC # 68382-255-01

Reported: November 15, 2023 Initiated: October 19, 2023 #D-0096-2024

Product Description

Oxybutynin Chloride Extended-Release Tablet USP, 5 mg, 100 count bottles, Rx Only, Manufactured by: Cadila Healthcare Ltd, Baddi, India. Distributed by: Zydus Pharmaceuticals (USA) Inc. NDC # 68382-255-01

Reason for Recall

Failed Dissolution Specifications-out-of-specification (OOS) test results observed for dissolution at the 6 month long term time point.

Details

Distribution
Nationwide.
Location
Pennington, NJ

Frequently Asked Questions

What product was recalled?
Oxybutynin Chloride Extended-Release Tablet USP, 5 mg, 100 count bottles, Rx Only, Manufactured by: Cadila Healthcare Ltd, Baddi, India. Distributed by: Zydus Pharmaceuticals (USA) Inc. NDC # 68382-255-01. Recalled by Zydus Pharmaceuticals (USA) Inc.
Why was this product recalled?
Failed Dissolution Specifications-out-of-specification (OOS) test results observed for dissolution at the 6 month long term time point.
Which agency issued this recall?
This recall was issued by the FDA Drug on November 15, 2023. Severity: Moderate. Recall number: D-0096-2024.